Answers are grounded in this paper and cite their sources.
Introduction Arginase is overexpressed in many advanced cancers, which can deplete arginine in tumors to promote immunosuppression. Arginase inhibition may enhance the efficacy of standard chemotherapy regimens by increasing arginine levels and modulating arginine-mediated immune function. INCB001158 is a potent and selective arginase inhibitor that was assessed in combination with chemotherapy. Methods This was an open-label, nonrandomized, phase 1/2 dose-escalation/expansion study in adults with advanced or metastatic solid tumors. INCB001158 was administered orally twice daily (bid) in combination with chemotherapy (mFOLFOX6, gemcitabine/cisplatin, or paclitaxel). Phase 2 tumor-type cohorts were colorectal cancer, biliary tract cancer (BTC), ovarian cancer (OC), gastroesophageal cancer, and endometrial cancer. Primary end points included safety, tolerability, and overall response rate (ORR). Results Fifty-four patients were enrolled in phase 1 and 95 in phase 2. No dose-dependent adverse event trends were observed. Recommended phase 2 dose of INCB001158 was 100 mg bid. Two phase 2 expansion cohorts met criteria for Simon 2-stage expansion: patients with BTC treated with INCB001158 100 mg bid plus gemcitabine/cisplatin, and patients with platinum-resistant OC treated with INCB001158 100 mg bid plus paclitaxel. The overall response rate was 24.2% (8/33 patients, all partial responses) in the BTC cohort and 16.7% (1/24 complete response and 3/24 partial responses) in the OC cohort. Pharmacodynamic increase in arginine levels was observed systemically in blood plasma and locally detected by mass-spectrometry images of tumor tissue. Conclusions INCB001158 was generally well tolerated and associated with increases in arginine levels and responses in the BTC cohort, suggesting that combination regimens with chemotherapy may provide clinical benefit for some patients. ClinicalTrials.gov ID: NCT03314935; EudraCT 2017–002904-29
No takes yet. Share an insight, caveat, or question.
Naing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: